NEW YORK/FRANKFURT (Reuters) - Merck (NSE:PROR) KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics ...

AOMORI—A tourism official’s attempt to produce an apple-themed version of Rubik’s Cube has led to several red faces. Apples are a specialty of Aomori Prefecture, and images of six varieties ...

Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...

2-Year U.S. Treasury Note Continuous Contract $102.730-0.008-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.453-0.023-0.02% 10-Year U.S. Treasury Note Continuous Contract $109.188-0.031 ...

Each of the three Galaxy S25 models delivers cutting-edge features and performance, but which one is right for you? Here’s everything you need to know about Samsung’s latest flagship phones. I ...

Merck KGaA, a prominent player in the global healthcare and technology sectors, is negotiating a significant acquisition deal with Springworks Therapeutics, a U.S. firm specializing in cancer and rare ...